Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIOK2 | Q9BVS4 | 7/20 | 0.67 |
| ▸ | GSK3A | P49840 | 3/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24598427 | 0.85 | NPC1 (0.51) | RIOK2GSK3AMAPK10ALDH1A1MAPT | |
| SCHEMBL25404170 | 0.83 | TP53 (0.64) | RIOK2GSK3AMAPK10ALDH1A1MAPT | |
| SCHEMBL24932361 | 0.82 | GCK (0.69) | RIOK2MTNR1BADORA3ALDH1A1MAPT | |
| SCHEMBL19728667 | 0.82 | RIOK2 (0.49) | RIOK2GSK3AMAPK10ADORA3ALDH1A1 | |
| SCHEMBL19728675 | 0.82 | RIOK2 (0.49) | RIOK2GSK3AMAPK10ALDH1A1MAPT | |
| SCHEMBL25189182 | 0.82 | RIOK2 (0.60) | RIOK2GSK3AMAPK10ALDH1A1MAPT | |
| SCHEMBL3932265 | 0.82 | RIOK2 (0.57) | RIOK2GSK3AMAPK10MTNR1BADORA3 | |
| SCHEMBL19728670 | 0.81 | RIOK2 (0.48) | RIOK2GSK3AMAPK10ALDH1A1MAPT | |
| SCHEMBL25402019 | 0.81 | NR3C2 (0.67) | RIOK2GSK3AMAPK10ALDH1A1TP53 | |
| SCHEMBL19116535 | 0.81 | RIOK2 (0.60) | RIOK2GSK3AMAPK10MTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RIOK2 2619/4885GSK3A 3009/4885MAPK10 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.